Michael J. Rybak

814 total citations · 1 hit paper
18 papers, 610 citations indexed

About

Michael J. Rybak is a scholar working on Infectious Diseases, Pharmacology and Molecular Medicine. According to data from OpenAlex, Michael J. Rybak has authored 18 papers receiving a total of 610 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 7 papers in Pharmacology and 6 papers in Molecular Medicine. Recurrent topics in Michael J. Rybak's work include Antimicrobial Resistance in Staphylococcus (7 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers) and Antibiotic Resistance in Bacteria (6 papers). Michael J. Rybak is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (7 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers) and Antibiotic Resistance in Bacteria (6 papers). Michael J. Rybak collaborates with scholars based in United States, Singapore and United Kingdom. Michael J. Rybak's co-authors include Linda Dresser, Ronda L. Akins, Dana Holger, Amer El Ghali, Nicholas Rebold, Ashlan J. Kunz Coyne, Taylor Morrisette, Peggy S. McKinnon, Melinda M. Neuhauser and Jacinda C. Abdul‐Mutakabbir and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and Drugs.

In The Last Decade

Michael J. Rybak

17 papers receiving 585 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa

2022 162 citations Ashlan J. Kunz Coyne, Amer El Ghali et al. Infectious Diseases and Therapy profile →

Peers

Michael J. Rybak

PHARM

Tsai-Ling Yang Lauderdale Taiwan

I‐Wen Huang Taiwan

Tomoo Saga Japan

Nicole Coffin United States

Jordan R. Smith United States

Linda A. Miller United States

Jeffrey R. Aeschlimann United States

Monika Kumaraswamy United States

Hamid Heidari Iran

Anne Santerre Henriksen Denmark

Tsai-Ling Yang Lauderdale Taiwan

Michael J. Rybak

167 ×0.6

363 ×2.0

245 ×1.5

140 ×0.9

PHARM

101 ×0.8

Citations per year, relative to Michael J. Rybak Michael J. Rybak (= 1×) peers Tsai-Ling Yang Lauderdale

Countries citing papers authored by Michael J. Rybak

Since Specialization

Citations

This map shows the geographic impact of Michael J. Rybak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Rybak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Rybak more than expected).

Fields of papers citing papers by Michael J. Rybak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Rybak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Rybak. The network helps show where Michael J. Rybak may publish in the future.

Co-authorship network of co-authors of Michael J. Rybak

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Rybak. A scholar is included among the top collaborators of Michael J. Rybak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Rybak. Michael J. Rybak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Kebriaei, Razieh, Jacinda C. Abdul‐Mutakabbir, Kyle Stamper, Katherine L. Lev, & Michael J. Rybak. (2023). Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin. Infectious Diseases and Therapy. 12(10). 2485–2494. 1 indexed citations

Coyne, Ashlan J. Kunz, et al.. (2023). 2066. Synergistic Bacteriophage-Antibiotic Combinations Against High Inoculum DNS MRSA. Open Forum Infectious Diseases. 10(Supplement_2).

Ghali, Amer El, et al.. (2023). 2118. Comparative Analysis of Cefiderocol Mono- and Combination Therapy for Multi-Drug Resistant Gram-negative Infections. Open Forum Infectious Diseases. 10(Supplement_2). 2 indexed citations

Zasowski, Evan J, Trang D Trinh, Kimberly C. Claeys, et al.. (2022). International Validation of a Methicillin-Resistant Staphylococcus aureus Risk Assessment Tool for Skin and Soft Tissue Infections. Infectious Diseases and Therapy. 11(6). 2253–2263. 6 indexed citations

Holger, Dana, Nicholas Rebold, Sara Alosaimy, et al.. (2022). Impact of Ceftolozane–Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections. Infectious Diseases and Therapy. 11(5). 1965–1980. 10 indexed citations

Rebold, Nicholas, Sara Alosaimy, Taylor Morrisette, et al.. (2022). Clinical Characteristics Associated with Bacterial Bloodstream Coinfection in COVID-19. Infectious Diseases and Therapy. 11(3). 1281–1296. 5 indexed citations

Coyne, Ashlan J. Kunz, Amer El Ghali, Dana Holger, Nicholas Rebold, & Michael J. Rybak. (2022). Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa. Infectious Diseases and Therapy. 11(2). 661–682. 162 indexed citations breakdown →

Morrisette, Taylor, Sara Alosaimy, Abdalhamid M Lagnf, et al.. (2022). Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens. Infectious Diseases and Therapy. 11(4). 1715–1723. 12 indexed citations

Morrisette, Taylor, Thomas P. Lodise, Marc H. Scheetz, et al.. (2020). The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. Infectious Diseases and Therapy. 9(3). 561–572. 19 indexed citations

10.

Kebriaei, Razieh, Katherine L. Lev, Taylor Morrisette, et al.. (2020). Bacteriophage-Antibiotic Combination Strategy: an Alternative against Methicillin-Resistant Phenotypes of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 64(7). 51 indexed citations

11.

Morrisette, Taylor, Sara Alosaimy, Jacinda C. Abdul‐Mutakabbir, Razieh Kebriaei, & Michael J. Rybak. (2020). The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA—Salvaging the Gold Standards with Combination Therapy. Antibiotics. 9(11). 762–762. 21 indexed citations

12.

Rybak, Michael J., Ben M. Lomaestro, John C. Rotschafer, Robert C. Moellering, & Donald P. Levine. (2009). Reply to Panday and Sturkenboom. Clinical Infectious Diseases. 49(12). 1965–1966. 1 indexed citations

13.

Rybak, Michael J.. (2004). Increased Bacterial Resistance: PROTEKT US--An Update. Annals of Pharmacotherapy. 38(9_suppl). S8–S13. 7 indexed citations

14.

Kaatz, Glenn W. & Michael J. Rybak. (2001). Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria. PubMed. 6(1). 43–55. 5 indexed citations

15.

Rybak, Michael J. & Ronda L. Akins. (2001). Emergence of Methicillin-Resistant Staphylococcus aureus with Intermediate Glycopeptide Resistance. Drugs. 61(1). 1–7. 93 indexed citations

16.

Foster, David R. & Michael J. Rybak. (1999). Pharmacologic and Bacteriologic Properties of SCH‐27899 (Ziracin), an Investigational Antibiotic from the Everninomicin Family. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 19(10). 1111–1117. 20 indexed citations

17.

McKinnon, Peggy S., et al.. (1999). Outcome Assessment of Minimizing Vancomycin Monitoring and Dosing Adjustments. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 19(3). 257–266. 65 indexed citations

18.

Dresser, Linda & Michael J. Rybak. (1998). The Pharmacologic and Bacteriologic Properties of Oxazolidinones, a New Class of Synthetic Antimicrobials. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 18(3). 456–462. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact